Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Alzheimer's and Dementia

Volumn 13, Issue 3, 2017, Pages 285-295

  Herukka, Sanna Kaisa ^a   Simonsen, Anja Hviid ^b   Andreasen, Niels ^c   Baldeiras, Ines ^d   Bjerke, Maria ^e   Blennow, Kaj ^f   Engelborghs, Sebastiaan ^e,g   Frisoni, Giovanni B ^h,i   Gabryelewicz, Tomasz ^j   Galluzzi, Samantha ⁱ   Handels, Ron ^k   Kramberger, Milica G ^l   Kulczyńska, Agnieszka ^m   Molinuevo, Jose Luis ^n,o   Mroczko, Barbara ^m   Nordberg, Agneta ^p   Oliveira, Catarina Resende ^d   Otto, Markus ^q   Rinne, Juha O ^r   Rot, Uroš ^l   Saka, Esen ^s   Soininen, Hilkka ^a   Struyfs, Hanne ^e   Suardi, Silvia ^t   Visser, Pieter Jelle ^u,v   Winblad, Bengt ^p   Zetterberg, Henrik ^f,w   Waldemar, Gunhild ^b   more..

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b University of Copenhagen   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e UNIVERSITY OF ANTWERP   (Belgium)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g Hospital Network Antwerp (ZNA) Hoge Beuken and Middelheim   (Belgium)

^h UNIVERSITY OF GENEVA   (Switzerland)

ⁱ IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^j MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^m MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o BarcelonaBeta Brain Research Center BBRC   (Spain)

^p KAROLINSKA INSTITUTE   (Sweden)

^q UNIVERSITY OF ULM   (Germany)

^r TURKU UNIVERSITY HOSPITAL   (Finland)

^s HACETTEPE UNIVERSITY   (Turkey)

^t DEPARTMENT OF NEUROSURGERY   (Italy)

^u MAASTRICHT UNIVERSITY   (Netherlands)

^v VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^w UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Alzheimer's disease; Biomarkers; CSF; Diagnostics; GRADE; Mild cognitive impairment; Recommendations

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN; FLUORODEOXYGLUCOSE F 18; GLIAL FIBRILLARY ACIDIC PROTEIN; HEART FATTY ACID BINDING PROTEIN; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; NEURON SPECIFIC ENOLASE; PHOSPHOPROTEIN; PHOSPHORYLATED TAU PROTEIN; PITTSBURGH COMPOUND B; SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA FRAGMENT; SOLUBLE AMYLOID PRECURSOR PROTEIN BETA FRAGMENT; TAU PROTEIN; UNCLASSIFIED DRUG; VISININ LIKE PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE COURSE; HEALTH CARE COST; HUMAN; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SHORT SURVEY; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); WELLBEING; CEREBROSPINAL FLUID; COGNITIVE DYSFUNCTION; MEDLINE; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITIVE DYSFUNCTION; HUMANS; MEDLINE; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 85007323510     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.09.009     Document Type: Short Survey

References (51)

1. [1] Blennow, K., de Leon, M.J., Zetterberg, H., Alzheimer's disease. Lancet 368 (2006), 387–403.
2. [2] Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
3. [3] Petersen, R.C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., Fratiglioni, L., Mild cognitive impairment: a concept in evolution. J Intern Med 275 (2014), 214–228.
4. [4] Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.O., et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256 (2004), 240–246.
5. [5] Mitchell, A.J., Shiri-Feshki, M., Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 119 (2009), 252–265.
6. [6] Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
7. [7] Olsson, B., Lautner, R., Andreasson, U., Ohrfelt, A., Portelius, E., Bjerke, M., et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol 15 (2016), 673–684.
8. [8] Mo, J.A., Lim, J.H., Sul, A.R., Lee, M., Youn, Y.C., Kim, H.J., Cerebrospinal fluid beta-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease—systematic review and meta-analysis. PLoS One, 10, 2015, e0116802.
9. [9] Ferreira, D., Rivero-Santana, A., Perestelo-Perez, L., Westman, E., Wahlund, L.O., Sarria, A., et al. Improving CSF biomarkers' performance for predicting progression from mild cognitive impairment to Alzheimer's disease by considering different confounding factors: a meta-analysis. Front Aging Neurosci, 6, 2014, 287.
10. [10] Ritchie, C., Smailagic, N., Noel-Storr, A.H., Takwoingi, Y., Flicker, L., Mason, S.E., et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev(6), 2014, CD008782.
11. [11] Ferreira, L., Ferreira Santos-Galduroz, R., Ferri, C.P., Fernandes Galduroz, J.C., Rate of cognitive decline in relation to sex after 60 years-of-age: a systematic review. Geriatr Gerontol Int 14 (2014), 23–31.
12. [12] Noel-Storr, A.H., Flicker, L., Ritchie, C.W., Nguyen, G.H., Gupta, T., Wood, P., et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimers Dement 9 (2013), e96–e105.
13. [13] van Rossum, I.A., Vos, S., Handels, R., Visser, P.J., Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 20 (2010), 881–891.
14. [14] Schmand, B., Huizenga, H.M., van Gool, W.A., Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 40 (2010), 135–145.
15. [15] Mitchell, A.J., CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80 (2009), 966–975.
16. [16] Diniz, B.S., Pinto Junior, J.A., Forlenza, O.V., Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 9 (2008), 172–182.
17. [17] Bocchetta, M., Galluzzi, S., Kehoe, P.G., Aguera, E., Bernabei, R., Bullock, R., et al. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Alzheimers Dement 11 (2015), 195–206.e1.
18. [18] Molinuevo, J.L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret-Liaudet, A., et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 10 (2014), 808–817.
19. [19] Schunemann, H.J., Oxman, A.D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G.E., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336 (2008), 1106–1110.
20. [20] Brozek, J.L., Akl, E.A., Jaeschke, R., Lang, D.M., Bossuyt, P., Glasziou, P., et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 64 (2009), 1109–1116.
21. [21] Leone, M.A., Brainin, M., Boon, P., Pugliatti, M., Keindl, M., Bassetti, C.L., European Federation of Neurological Societies. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces—revised recommendations 2012. Eur J Neurol 20 (2013), 410–419.
22. [22] Simonsen, A.H., Herukka, S-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement, 2016 In press.
23. [23] Mattsson, N., Insel, P.S., Landau, S., Jagust, W., Donohue, M., Shaw, L.M., et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol 1 (2014), 534–543.
24. [24] Duits, F.H., Martinez-Lage, P., Paquet, C., Engelborghs, S., Lleo, A., Hausner, L., et al. Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement 12 (2016), 154–163.
25. [25] Vos, S.J., Verhey, F., Frolich, L., Kornhuber, J., Wiltfang, J., Maier, W., et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 138 (2015), 1327–1338.
26. [26] Zwan, M.D., Rinne, J.O., Hasselbalch, S.G., Nordberg, A., Lleo, A., Herukka, S.K., et al. Use of amyloid-PET to determine cutpoints for CSF markers: a multicenter study. Neurology 86 (2016), 50–58.
27. [27] Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D.J., et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 71 (2014), 1282–1289.
28. [28] Rosen, C., Farahmand, B., Skillback, T., Nagga, K., Mattsson, N., Kilander, L., et al. Benchmarking biomarker-based criteria for Alzheimer's disease: data from the Swedish Dementia Registry, SveDem. Alzheimers Dement 11 (2015), 1470–1479.
29. [29] Galasko, D., Chang, L., Motter, R., Clark, C.M., Kaye, J., Knopman, D., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998), 937–945.
30. [30] Sunderland, T., Mirza, N., Putnam, K.T., Linker, G., Bhupali, D., Durham, R., et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56 (2004), 670–676.
31. [31] Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (2009), 403–413.
32. [32] Vemuri, P., Wiste, H.J., Weigand, S.D., Knopman, D.S., Shaw, L.M., Trojanowski, J.Q., et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67 (2010), 308–316.
33. [33] Mattsson, N., Rosen, E., Hansson, O., Andreasen, N., Parnetti, L., Jonsson, M., et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78 (2012), 468–476.
34. [34] Ngandu, T., Lehtisalo, J., Solomon, A., Levalahti, E., Ahtiluoto, S., Antikainen, R., et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385 (2015), 2255–2263.
35. [35] Silverman, D.H., Cummings, J.L., Small, G.W., Gambhir, S.S., Chen, W., Czernin, J., et al. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 4 (2002), 283–293.
36. [36] Moulin-Romsee, G., Maes, A., Silverman, D., Mortelmans, L., Van Laere, K., Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. Eur J Neurol 12 (2005), 254–263.
37. [37] Wimo, A., Ballard, C., Brayne, C., Gauthier, S., Handels, R., Jones, R.W., et al. Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. J Intern Med 275 (2014), 304–316.
38. [38] Hort, J., O'Brien, J.T., Gainotti, G., Pirttila, T., Popescu, B.O., Rektorova, I., et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 17 (2010), 1236–1248.
39. [39] McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R. Jr., Kawas, C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
40. [40] Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H., et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 19 (2012), 1159–1179.
41. [41] Lautner, R., Palmqvist, S., Mattsson, N., Andreasson, U., Wallin, A., Palsson, E., et al. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry 71 (2014), 1183–1191.
42. [42] Valcarcel-Nazco, C., Perestelo-Perez, L., Molinuevo, J.L., Mar, J., Castilla, I., Serrano-Aguilar, P., Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease. J Alzheimers Dis 42 (2014), 777–788.
43. [43] Bossuyt, P.M.M., McCaffery, K., Additional patient outcomes and pathways in evaluations of testing, in anonymous. 2009, Medical Tests—White Paper Series, Rockville MD.
44. [44] Lee, D.W., Neumann, P.J., Rizzo, J.A., Understanding the medical and nonmedical value of diagnostic testing. Value Health 13 (2010), 310–314.
45. [45] Raschetti, R., Albanese, E., Vanacore, N., Maggini, M., Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med, 4, 2007, e338.
46. [46] Russ, T.C., Morling, J.R., Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev, 9, 2012, CD009132.
47. [47] Cooper, C., Li, R., Lyketsos, C., Livingston, G., Treatment for mild cognitive impairment: systematic review. Br J Psychiatry 203 (2013), 255–264.
48. [48] Frank, L., Lloyd, A., Flynn, J.A., Kleinman, L., Matza, L.S., Margolis, M.K., et al. Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants. Int Psychogeriatr 18 (2006), 151–162.
49. [49] Lingler, J.H., Nightingale, M.C., Erlen, J.A., Kane, A.L., Reynolds, C.F. 3rd, Schulz, R., et al. Making sense of mild cognitive impairment: a qualitative exploration of the patient's experience. Gerontologist 46 (2006), 791–800.
50. [50] Joosten-Weyn Banningh, L., Vernooij-Dassen, M., Rikkert, M.O., Teunisse, J.P., Mild cognitive impairment: coping with an uncertain label. Int J Geriatr Psychiatry 23 (2008), 148–154.
51. [51] Beard, R.L., Neary, T.M., Making sense of nonsense: experiences of mild cognitive impairment. Sociol Health Illn 35 (2013), 130–146.